- Home
- CANF vs BFRI Comparison
CANF vs BFRI Comparison
Compare CANF & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- BFRI
- Stock Information
- Founded
- CANF 1994
- BFRI 1997
- Country
- CANF Israel
- BFRI United States
- Employees
- CANF N/A
- BFRI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- BFRI Health Care
- Exchange
- CANF Nasdaq
- BFRI Nasdaq
- Market Cap
- CANF 9.6M
- BFRI 11.4M
- IPO Year
- CANF N/A
- BFRI 2021
- Fundamental
- Price
- CANF $0.59
- BFRI $1.04
- Analyst Decision
- CANF Strong Buy
- BFRI Strong Buy
- Analyst Count
- CANF 2
- BFRI 1
- Target Price
- CANF $14.50
- BFRI $2.75
- AVG Volume (30 Days)
- CANF 174.9K
- BFRI 98.6K
- Earning Date
- CANF 11-27-2025
- BFRI 11-12-2025
- Dividend Yield
- CANF N/A
- BFRI N/A
- EPS Growth
- CANF N/A
- BFRI N/A
- EPS
- CANF N/A
- BFRI N/A
- Revenue
- CANF $560,000.00
- BFRI $39,188,000.00
- Revenue This Year
- CANF $461.72
- BFRI $11.07
- Revenue Next Year
- CANF N/A
- BFRI $11.20
- P/E Ratio
- CANF N/A
- BFRI N/A
- Revenue Growth
- CANF N/A
- BFRI 11.20
- 52 Week Low
- CANF $0.59
- BFRI $0.54
- 52 Week High
- CANF $3.12
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- CANF 32.24
- BFRI 63.35
- Support Level
- CANF $0.60
- BFRI $0.93
- Resistance Level
- CANF $0.64
- BFRI $1.09
- Average True Range (ATR)
- CANF 0.03
- BFRI 0.07
- MACD
- CANF 0.00
- BFRI 0.01
- Stochastic Oscillator
- CANF 2.03
- BFRI 79.79
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.